Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could ditching Beta-Blockers boost quality of life for seniors with heart failure?

NCT ID NCT07298993

Symptom relief Sponsor: Weill Medical College of Cornell University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jul 16, 2026 · Updated 3 times

Summary

This study looks at whether gradually stopping beta-blockers (medicines often used for heart failure) can improve symptoms and daily function in adults aged 60 and older with a specific type of heart failure called HFpEF. About 240 participants will either taper off their beta-blocker or continue it, and researchers will track hospitalizations, quality of life, and mood over 4 months. The goal is to see if removing these medications, when they may no longer be needed, leads to better outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
beta-blockers (atenolol, bisoprolol, carvedilol, metoprolol succinate, metoprolol tartrate)
What this could lead to
If successful, this could show that stopping unnecessary beta-blockers helps older adults with HFpEF feel better and have fewer hospitalizations.
What could go wrong
This is a small, early-phase study (240 participants) focused on symptom improvement, not a cure. Results may not apply to all patients, and stopping beta-blockers could carry risks like increased heart rate or blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Ambulatory adults age ≥60 years with HFpEF (EF ≥50% based on most recent transthoracic echocardiogram) 2. Hospitalized with HF in the past 24 months (defined by diagnostic codes in any position) 3. Taking any of the following ß-blockers: atenolol, bisoprolol, carvedilol, metoprolol succinate, or metoprolol tartrate (i.e., pharmacy prescription data) 4. Kaiser Permanence Northern California Membership Exclusion Criteria: 1. Alternative etiologies of HFpEF syndrome 2. Compelling guideline indication for ß-blocker: * Prior EF \<50% (i.e., based on the structured data field on transthoracic echocardiogram) * Current anginal symptoms (i.e., based on the Rose Angina single-question screener for angina) * MI (i.e., diagnostic codes) and/or coronary revascularization (i.e., procedure codes) within 3 years * Hospitalization for a primary discharge diagnosis of atrial fibrillation or atrial flutter in the prior 12 months * Other documented reason in the opinion of the treating provider and/or enrolling clinician-investigator 3. Evidence of recent decompensated HF * Hospitalization for a primary discharge diagnosis of HF within the past 30 days * Change in loop diuretic pharmacy prescription in the past 30 days (i.e. pharmacy prescription data) (Note: This definition is based on documented prescription changes and does not include short-term dose adjustments that were verbally communicated to the patient by their provider.) 4. Estimated life expectancy \<6 months (i.e., diagnostic codes) 5. Diagnosed dementia (i.e.., diagnostic codes) 6. Unable to provide informed consent 7. Loss of Kaiser Permanence Northern California Membership

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diastolic heart failure heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure HFPEF Hfpef - heart failure with preserved ejection fraction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Kaiser Permanente Northern California (KPNC)

    Pleasanton, California, 94588, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.